Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms

被引：0

作者：

Gurler, Fatih ^{[1
,8
]}

Esen, Selin Akturk ^{[2
]}

Inci, Bediz Kurt ^{[3
]}

Sutcuoglu, Osman ^{[4
]}

Ucar, Gokhan ^{[2
]}

Akdogan, Orhun ^{[5
]}

Uncu, Dogan ^{[2
]}

Turhan, Nesrin ^{[6
]}

Akyurek, Nalan ^{[7
]}

Ozdemir, Nuriye ^{[4
]}

Ozet, Ahmet ^{[4
]}

Yazici, Ozan ^{[4
]}

机构：

[1] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkiye

[2] Univ Hlth Sci, Ankara City Hosp, Dept Med Oncol, Ankara, Turkiye

[3] Aksaray Training & Res Hosp, Dept Med Oncol, Aksaray, Turkiye

[4] Gazi Univ, Sch Med, Dept Med Oncol, Ankara, Turkiye

[5] Yenimahalle Training & Res Hosp, Dept Internal Med, Ankara, Turkiye

[6] Univ Hlth Sci, Ankara City Hosp, Dept Pathol, Ankara, Turkiye

[7] Gazi Univ, Sch Med, Dept Pathol, Ankara, Turkiye

[8] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Yenimahalle Ankara, Turkiye

来源：

CANCER INVESTIGATION | 2024年 / 42卷 / 02期

关键词：

PD-L1; LAG-3; TIM-3; OX40L; MSI; TUMOR-INFILTRATING LYMPHOCYTES; MICROSATELLITE INSTABILITY; PHASE-II; CANCER; PATHWAYS; EFFICACY; PROTEIN; SAFETY; CD223;

D O I：

10.1080/07357907.2024.2330102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks. Of 83 patients, PD-L1 expression was observed in 18.1% (n = 15) of the patients. None of the patients exhibited LAG-3 expression. TIM-3 expression was 4.9% (n = 4), OX40L was 22.9% (n = 19), and 8.4% (n = 7) of the patients had MSI tumor. A low-to-intermediate positive correlation was observed between PD-L1 and TIM-3 expressions (rho: 0.333, p < 0.01). Although PD-L1 expression was higher in grade 3 NET/NEC, MSI status was prominent in grade 1/2 NET.

引用

页码：141 / 154

页数：14

共 50 条

[31] Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database [J].

Frey, Connor ;

Etminan, Mahyar .

ANTIBODIES, 2024, 13 (03)

[32] Expressions of PD-L1 and FOXP3 in uterine cervical neoplasms may indicate tumor invasion and squamous differentiation [J].

Sayhan, Sevil ;

Diniz, Gulden ;

Ayaz, Duygu ;

Kahraman, Dudu Solakoglu .

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (04) :769-774

[33] 探讨Tim-3和PD-1/PD-L1在非小细胞肺癌中表达的意义 [J].

于少华 ;

张易青 .

中西医结合心血管病电子杂志, 2020, 8 (30) :24-24

[34] 非小细胞肺癌中TIM-3、PD-1、PD-L1的表达与临床意义 [J].

高锋 ;

钱文霞 ;

冯一中 .

海南医学, 2019, 30 (02) :154-158

[35] Beyond PD-L1: Assessment of LAG-3 and other predictive biomarkers in non-small cell lung carcinoma [J].

Hung, Yin P. ;

Mino-Kenudson, Mari .

CANCER CYTOPATHOLOGY, 2023, 131 (03) :151-153

[36] Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance [J].

Sun, Yao ;

Zhou, Xin ;

Lucas, Elena ;

Chen, Lili ;

Zhang, Huijuan ;

Chen, Hao ;

Zhou, Feng .

JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2024, 10 (01)

[37] 原发性干燥综合征患者外周血OX40、OX40L、PD-1、PD-L1和SPD-1的表达及临床意义 [J].

郑戈 ;

袁一梦 .

临床误诊误治, 2017, 30 (10) :83-87

[38] PD-1/PD-L1、TIM-3表达与食管癌临床病理特征及预后的关系 [J].

刘凯 ;

刘燕 ;

黄莉 ;

刘凯 .

重庆医学, 2022, 51 (01) :65-69

[39] PD-1、PD-L1、TIM-3表达与食管癌临床病理特征及预后的关系 [J].

杨硕 ;

陈颖 .

实用癌症杂志, 2024, 39 (05) :778-780

[40] The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia-A Narrative Review [J].

Mittelberger, Johanna ;

Seefried, Marina ;

Franitza, Manuela ;

Garrido, Fabian ;

Ditsch, Nina ;

Jeschke, Udo ;

Dannecker, Christian .

MEDICINA-LITHUANIA, 2022, 58 (02)

← 1 2 3 4 5 →